

### Awareness and management of conflicts of interest

Schneider, Nils

Postprint / Postprint

Zeitschriftenartikel / journal article

Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:

[www.peerproject.eu](http://www.peerproject.eu)

#### Empfohlene Zitierung / Suggested Citation:

Schneider, N. (2010). Awareness and management of conflicts of interest. *Journal of Public Health*, 18(6), 597-600.  
<https://doi.org/10.1007/s10389-010-0350-x>

#### Nutzungsbedingungen:

Dieser Text wird unter dem "PEER Licence Agreement zur Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden Sie hier: <http://www.peerproject.eu> Gewährt wird ein nicht exklusives, nicht übertragbares, persönliches und beschränktes Recht auf Nutzung dieses Dokuments. Dieses Dokument ist ausschließlich für den persönlichen, nicht-kommerziellen Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments müssen alle Urheberrechtshinweise und sonstigen Hinweise auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses Dokument nicht in irgendeiner Weise abändern, noch dürfen Sie dieses Dokument für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder anderweitig nutzen.

Mit der Verwendung dieses Dokuments erkennen Sie die Nutzungsbedingungen an.

**gesis**  
Leibniz-Institut  
für Sozialwissenschaften

#### Terms of use:

This document is made available under the "PEER Licence Agreement". For more information regarding the PEER-project see: <http://www.peerproject.eu> This document is solely intended for your personal, non-commercial use. All of the copies of this documents must retain all copyright information and other information regarding legal protection. You are not allowed to alter this document in any way, to copy it for public or commercial purposes, to exhibit the document in public, to perform, distribute or otherwise use the document in public.

By using this particular document, you accept the above-stated conditions of use.

Mitglied der  
  
Leibniz-Gemeinschaft

Editorial Manager(tm) for Journal of Public Health  
Manuscript Draft

Manuscript Number: JOPH-D-10-00009R1

Title: Awareness and management of conflicts of interest

Article Type: Comment

Corresponding Author: Dr Nils Schneider, MD, MPH

Corresponding Author's Institution: Hannover Medical School

First Author: Nils Schneider, MD, MPH

Order of Authors: Nils Schneider, MD, MPH

Abstract: Aim: To discuss conflicts of interest and their impact on health care practice, policy and science.

Methods: Selective literature review and own empirical studies.

Results and conclusions: There is growing pressure on medical practitioners, researchers and policy makers to face up to the subject of conflicts of interest which is a very topical and controversial one in different areas of the health care system. Conflicts of interest are often unavoidable but there is nothing dishonourable about this and it does not in itself either detract from the value of the research and clinical work being done or impugn the integrity of the people doing it. However, the issue becomes critical when possible conflicts of interest are ignored. Inadequate awareness and transparency may cause substantial damage, both to the quality of research and clinical practice, and also to the reputations of individuals and of the medical profession and the scientific community as a whole. Therefore, to deal constructively with conflicts of interest we particularly need to enhance the awareness and transparency.

Response to Reviewers: Thank you very much for the reviews. The manuscript was thoroughly revised to take account of your comments. (New and additional text is marked in red.)

Reviewer 1:

The focus on non-financial conflicts of interest was strengthened to make the original aspects of the paper more explicit (please also see the response to reviewer 2).

Reviewer 2:

The focus on non-financial conflicts of interest was strengthened and broadened, and a personal example is given to illustrate the problem (page 6/7).

Thank you very much for the reference. Now the paper refers to Martinson et al. (pages 6 and 8).

Examples for different kinds of publication bias are given on page 3/4 together with additional references (Dickersin 1990, Dwan et al. 2008).

The spelling mistakes were corrected.

## **Awareness and management of conflicts of interest**

Nils Schneider

Correspondence:

Priv.-Doz. Dr. Nils Schneider, MD, MPH

Hannover Medical School, Institute of Epidemiology, Social Medicine and Health  
System Research, Carl Neuberg Str. 1, 30626 Hannover, Germany

Phone: ++49 511 532 8426

Fax: ++49 511 532 8426

Email: [schneider.nils@mh-hannover.de](mailto:schneider.nils@mh-hannover.de)

## Abstract

1  
2  
3 Aim: To discuss conflicts of interest and their impact on health care practice, policy  
4  
5 and science.  
6

7  
8 Methods: Selective literature review and own empirical studies.  
9

10  
11 Results and conclusions: There is growing pressure on medical practitioners,  
12  
13 researchers and policy makers to face up to the subject of conflicts of interest which  
14  
15 is a very topical and controversial one in different areas of the health care system.  
16  
17 Conflicts of interest are often unavoidable but there is nothing dishonourable about  
18  
19 this and it does not in itself either detract from the value of the research and clinical  
20  
21 work being done or impugn the integrity of the people doing it. However, the issue  
22  
23 becomes critical when possible conflicts of interest are ignored. Inadequate  
24  
25 awareness and transparency may cause substantial damage, both to the quality of  
26  
27 research and clinical practice, and also to the reputations of individuals and of the  
28  
29 medical profession and the scientific community as a whole. Therefore, to deal  
30  
31 constructively with conflicts of interest we particularly need to enhance the  
32  
33 awareness and transparency.  
34  
35  
36  
37  
38  
39

40  
41 **Key words:** conflicts of interest, health services research, public health,  
42  
43 transparency  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Text

1  
2  
3 The subject of conflicts of interest is a very topical and controversial one in a number  
4  
5 of different areas of the health care system. Examples of such areas are in-service  
6  
7 training events for doctors that are sponsored by the pharmaceutical industry and  
8  
9 visits to hospitals and doctors' surgeries by industry representatives (Moynihan 2008;  
10  
11 Carney et al. 2001; Wazana 2000). Links between medical research and related  
12  
13 sectors of industry are also increasingly giving rise to critical debate both among  
14  
15 professionals and in the public domain (Agnell 2000; DeAngelis 2006). There is  
16  
17 growing pressure on medical practitioners, researchers and policy makers to face up  
18  
19 to these issues.  
20  
21  
22  
23  
24

25 In the theoretical discussion within the sector, a distinction is made between primary  
26  
27 and secondary interests. Primary interests relate to the fundamental concerns and  
28  
29 objectives involved in the exercise of a profession (Thompson 1993). These vary,  
30  
31 depending on what area of professional activity is involved in each case. For  
32  
33 physicians engaged in clinical practice, for example, the primary interest as defined  
34  
35 from this point of view is to provide the individual patient with the best possible  
36  
37 treatment; for researchers it is to produce valid new results; while for politicians  
38  
39 concerned with the organisation of health care it is to create a system providing the  
40  
41 best possible framework of conditions. Secondary interests, on the other hand, relate  
42  
43 to circumstances which have material or social consequences that might influence  
44  
45 people's judgments. This may express itself in many different ways, for example in  
46  
47 the form of taking only one side of an argument into consideration, or of avoiding  
48  
49 asking awkward questions, or else of not pursuing the search for scientific insights to  
50  
51 sufficient depths (Klemperer 2008).  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Such secondary interests do not automatically imply negative consequences. The  
2 quest for academic success (as measured by reputation, the number of publications  
3 and the ability to tap into new sources of funding) is a secondary interest among  
4 researchers which may initially be assumed to exert a positive influence on the  
5 primary scientific interest of gaining valid new findings. Practising physicians for their  
6 part draw a large proportion of their social status from the doctor/patient relationship;  
7 the enhancement of this status represents a secondary interest that is capable of  
8 influencing positively the basic concern of the medical practitioner to provide his  
9 patients with the best possible care. These examples show that primary and  
10 secondary interests are closely interlinked, and in the ideal case represent important  
11 drivers of progress, development and the quality of care.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 However, secondary interests may also have substantial negative consequences,  
28 and one essential aspect of the matter is the fact that we are often not aware of, or  
29 prefer to close our eyes to, this problem (DeAngelis 2006; Klemperer 2008;  
30 Schneider 2008).  
31  
32  
33  
34  
35  
36

### 37 **Lobbying activities**

38  
39  
40 As mentioned above, among the problematic areas is the influence of the  
41 pharmaceutical industry on research. For example, studies sponsored by the industry  
42 produce results favourable towards a particular product and a particular diagnostic or  
43 therapeutic procedure more frequently than do studies that are not sponsored by the  
44 industry (Bekelmann et al. 2003; Bell et al. 2006; Lexchin et al. 2003). **This may be  
45 due, among other factors, to the choice of study design, the questions asked of the  
46 data collected or publication bias. Publication bias occurs when the publication of  
47 results depends on their nature and direction (Dickersin 1990). For example, positive  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

or statistically significant results are more likely to be published than negative or inconclusive findings (Dwan et al. 2008).

Where researchers are heavily dependent on acquiring outside funding, this fact fosters a tendency to reach conclusions or publish results that will be popular with whoever is providing the funding. If the researcher receiving the funds knows what results will best suit the sponsor making them available, his desire and need for further finance and for follow-up projects may create dependencies which – consciously or unconsciously – influence the scientific work (Klemperer 2008).

Another critical point is the closeness to the industry of those who write clinical guidelines. Choudry et al. (2002) showed that four out of five authors of such guidelines had links to the pharmaceutical industry; and of these four, two were even employees or consultants of companies whose preparations they recommended in their guidelines.

Although the pharmaceutical industry is at the focus of the debate on conflicts of interest, these may also be triggered by other players such as the medical technology industry, professional associations, health insurance funds or government authorities. In view of the all-pervasiveness of lobbying activities in the health care sector, there are plenty of temptations at all levels – whether it is the clinical, the scientific or the political/organisational level – to succumb to influence or accept inducements.

It will never be possible to avoid conflicts of interest. Cooperation between researchers and the pharmaceutical industry, for example, is unavoidable, and indeed in many cases is even desirable and necessary – e.g. for the acquisition of

1 research funding or to foster the transfer of research findings into clinical practice and  
2 the development of new products.  
3

#### 4 **Awareness and transparency**

5  
6  
7  
8 There appears, however, to be a need for a cultural shift with regard to how to deal  
9 with this issue, a shift in the direction of an enhanced awareness of possible conflicts  
10 of interest and of transparency in respect of them.  
11  
12  
13

14  
15 Awareness means above all that both clinicians and researchers should give real  
16 consideration to the problem of possible conflicts of interests and should not, as can  
17 still frequently be observed, dismiss it with a superficial, knee-jerk reaction. It is an  
18 element of good academic practice to consider one's own position self-critically and  
19 to monitor the extent to which one is capable of forming independent judgments. It is  
20 up to researchers and practitioners to be aware of their responsibilities and to live out  
21 this awareness on the basis of the understanding they have of their own professional  
22 positions. It would be a dreadful thing if they were to be forced into giving the matter  
23 more serious consideration only by increased pressure from outside (from  
24 government, the media or the courts).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Transparency can be enhanced by the disclosure of any potential conflicts of interest.  
42  
43 In the academic world, the arrangement whereby publications are accompanied by a  
44 conflicts of interest statement is an important instrument pointing in this direction. The  
45 International Committee of Medical Journal Editors (ICMJE) has issued  
46 internationally recognised recommendations with regard to the criteria to be applied;  
47 these provide for information to be given not only on possible financial conflicts of  
48 interest, but on non-financial ones **such as personal relationships, intellectual passion**  
49 **or scientific competition** as well.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 Even though an increasing number of scientific journals nowadays expect their  
2 authors to provide such details, the actual implementation is often still less than ideal.  
3  
4 **Martinson et al. (2005) found out that not properly disclosing involvement in firms**  
5 **whose products are based on one`s own relationship belongs to the top ten**  
6 **misbehaviours of scientists.** Schneider et al. (2007) investigated the practice of  
7 disclosing conflicts of interest in German publications concerning health services  
8  
9 research: a mere 9% of the articles investigated (11 out of 124 publications) provided  
10 the reader with information on possible conflicts. This was due to the fact that only  
11  
12 58% (18 out of 31) of the journals concerned expected their authors to disclose  
13 conflicts of interest when submitting manuscripts; while even those magazines that  
14 expected such details from their authors often did not publish them, and so did not  
15 make them transparent to the reader. Furthermore, it was noticeable that where  
16 information on conflicts of interest was given, this related first and foremost to  
17 financial relationships, whereas non-financial conflicts of interest were largely  
18 ignored.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 This is doubtless due among other things to the fact that, compared with financial  
38 ones, intellectual and social conflicts of interest are more difficult to define, and also  
39 to the fact that they may impinge particularly closely to the personality and personal  
40 sphere of the scientist concerned. **This may be illustrated by the following example:**  
41  
42 **Recently, I reviewed a manuscript on new models of care for a specific group of**  
43 **patients. The authors had carried out a survey with physicians who were potential**  
44 **collaborators with the specific services to examine barriers, incentives, and the**  
45 **physicians` professional self-image regarding the new models of care. Some of the**  
46 **authors have participated in the establishment of the services which were subject of**  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 the study and act as well known pacemakers in the field. In the manuscript they  
2 stated that there were no conflicts of interest.  
3

4  
5 However, I wondered if possibly there were conflicts of interest due to intellectual or  
6 social reasons. In their response to my review the authors negated this and  
7 explained: “We surely have conducted our research with a high level of  
8 personal commitment and intellectual passion – for us a method to ensure the  
9 quality, profundity and complexity required for a scientific approach of the  
10 (medical) world.”  
11  
12

13  
14  
15  
16  
17  
18  
19  
20 It becomes clear how difficult it is in particular cases to decide if there were non-  
21 financial circumstances that should be mentioned – or not – in a conflict of interest  
22 statement. On the one hand, obviously, non-financial conflicts can occur for a reason  
23 such as intellectual passion (ICMJE 2008); it might influence the researchers`  
24 judgments in planning and conducting a study and interpreting the results, e.g. in the  
25 form of avoiding asking awkward questions or taking only one side of an argument  
26 into consideration. On the other hand, however, a high level of intellectual passion is  
27 the basic motive for research; it is inherent to the scientific system. Is there any  
28 benefit if intellectual passion was declared in a conflict of interest statement? How to  
29 define standards?  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Overall, compared to financial relationships, demands for the disclosure of  
46 intellectual and social conflicts of interest are more likely to run into obstacles -  
47 although this is no grounds for not making the attempt to achieve a greater degree of  
48 awareness and openness. Self-critical and balancing consideration of these factors  
49 ought to be inherent in the academic process. This is particularly important as the  
50 modern scientist faces intensive pressure resulting from factors such as competition,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 regulatory, social and managerial demands which result in various possibilities for the  
3 compromise of scientific integrity (Martinson et al. 2005).  
4

## 5 **Dealing constructively with conflicts of interest**

6  
7  
8 In dealing constructively with the issue of conflicts of interest, it might be helpful to  
9  
10 take the following to heart: conflicts of interest will often be unavoidable, both in the  
11  
12 academic sphere and in clinical practice, but there is nothing dishonourable about  
13  
14 this and it does not in itself either detract from the value of the work being done or  
15  
16 impugn the integrity of the people doing it. But the issue becomes critical when  
17  
18 possible conflicts of interest are ignored. Inadequate awareness and transparency  
19  
20 may cause substantial damage, both to the quality of research and clinical practice,  
21  
22 and also to the reputations of individuals and of the medical profession and the  
23  
24 scientific community as a whole.  
25  
26  
27  
28

## 29 **Conflicts of interest**

30  
31  
32 The author declares that he has no conflict of interest.  
33  
34  
35

## 36 **References**

- 37  
38  
39 Agnell M. Is academic medicine for sale? (2000) N Engl J Med 342:1516-1518  
40  
41  
42 Bekelman J, Li Y, Gross C (2003) Scope and impact of financial conflicts of interests  
43  
44 in biomedical research: a systematic review. JAMA 289:454–65  
45  
46  
47 Bell C, Urbach D, Ray J, Bayoumi A, Rosen A, Greenberg D, Neumann P (2006)  
48  
49 Bias in published cost effectiveness studies: systematic review. BMJ 332:699–703  
50  
51  
52  
53 Carney SL, Nair KR, Sales MA, et al (2001) Pharmaceutical industry-sponsored  
54  
55 meetings: Good value or just a free meal? Intern Med J 31:488-491  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Choudhry N, Stelfox H, Detsky A (2002) Relationships between authors of clinical  
2 practice guidelines and the pharmaceutical industry. JAMA 287:612-617  
3

4 DeAngelis C (2006) The influence of money on medical science. JAMA 296:996-8  
5

6  
7  
8 Dickersin K (1990) The existence of publication bias and risk factors for its  
9 occurrence". JAMA 263:1385-1359  
10

11  
12  
13 Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, et al (2008) Systematic Review  
14 of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias.  
15

16  
17  
18 PLoS ONE 3:e3081  
19

20  
21 International Committee of Medical Journal Editors (2008) Uniform requirements for  
22 manuscripts submitted to biomedical journals: Writing and editing for biomedical  
23 publication. <http://www.ICMJE.org>. Accessed 25 December 2009  
24  
25

26  
27  
28 Klemperer D (2008) Interessenkonflikte. Gefahr für das ärztliche Urteilsvermögen.  
29  
30 Dtsch Arztebl 105:A2098-A2100  
31

32  
33  
34 Lexchin J, Bero L, Djulbegovic B, Clark O (2003) Pharmaceutical industry  
35 sponsorship and research outcome and quality: systematic review. BMJ 326:1167  
36  
37

38  
39  
40 Martinson BC, Anderson MS, de Vries R (2005) Scientists behaving badly. Nature  
41  
42 435:737-738  
43

44  
45  
46 Moynihan R (2008) Doctors` education. The invisible influence. BMJ 336: 416-417  
47

48  
49 Schneider N, Lingner H, Schwartz FW (2007) Disclosing conflicts of interest in  
50 German publications concerning health services research. BMC Health Serv Res  
51 7:78.  
52  
53

54  
55  
56 Schneider N, Lückmann SL (2008) Pharmasponsoring in der ärztlichen Fort und  
57  
58 Weiterbildung. Z Allg Med 84:516-524.  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Thompson DF (1993) Understanding financial conflicts of interest. N Engl J Med  
329:573-576

Wazana A (2000) Physicians and the pharmaceutical industry. JAMA 283:373-380.